Clinical outcomes of hepatocellular carcinoma surveillance in Melbourne, Australia
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16405 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Samuel Hui und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Early Detection of Cancer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Monash University.
Abstract (Originalsprache)
Background
Ultrasound surveillance for hepatocellular carcinoma (HCC) may improve early tumour detection but may additionally result in surveillance‐related harm through increased evaluation of non‐HCC lesions. The incidence of these outcomes has not been reported outside North America.
Aims
We aimed to report the outcomes of HCC surveillance with respect to both surveillance‐related benefits and harms.
Methods
We reviewed all HCC surveillance ultrasounds at a large Victorian tertiary hospital network in 2017 and followed their outcomes until 2021. Surveillance‐related benefits were defined as early‐stage HCC detection. Surveillance‐related harm was defined as contrast imaging, biopsies or surgery performed to evaluate non‐HCC liver lesions or false‐positive alpha‐fetoprotein levels.
Results
Five hundred and fifty‐three patients were included (mean age 54.5 ± 12.3 years, males 67.5%, cirrhosis 50.3%). The most common liver disease aetiology was hepatitis B (53.9%). Over a median of 4.7 years follow‐up, early‐stage HCC was detected in 3.3% (5.4% in cirrhotic vs 1.1% in non‐cirrhotic patients, P < 0.01). 75% of all HCCs were early‐stage. Surveillance‐related harm occurred in 12.5% (15.5% in cirrhotic vs 9.5% in non‐cirrhotic patients, P < 0.04), although most harm was mild (12.1%). In subgroup analysis, the detection of early‐stage HCC ranged between 0% (screened outside of guideline criteria and alcoholic cirrhotic patients) and 7.2% (hepatitis C cirrhosis). Harm occurred between 9% (non‐cirrhotic hepatitis B) and 20.8% (thrombocytopenia).
Conclusion
In our study, HCC surveillance was associated with early tumour detection, although many patients experienced mild surveillance‐related harm. Novel surveillance strategies and pathways are required to improve detection in high‐risk patients and minimise harm in low‐risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.
- Department of Gastroenterology and Hepatology, Monash Health, Melbourne, Victoria, Australia.
ORCID-Profile: Samuel Hui
Förderung
- Monash University
Zitieren
APA
Hui, S., Nguyen, A., Le, S., Dev, A., & Bell, S. (2024). Clinical outcomes of hepatocellular carcinoma surveillance in Melbourne, Australia. Internal Medicine Journal. https://doi.org/10.1111/imj.16405
Vancouver
Hui S, Nguyen A, Le S, Dev A, Bell S. Clinical outcomes of hepatocellular carcinoma surveillance in Melbourne, Australia. Internal Medicine Journal. 2024. doi:10.1111/imj.16405
BibTeX
@article{Hui2024,
author = {Hui, Samuel and Nguyen, Andrew and Le, Suong and Dev, Anouk and Bell, Sally},
title = {Clinical outcomes of hepatocellular carcinoma surveillance in Melbourne, Australia},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16405}
}
EUVIMED